Cardiovascular Risk Assessment Using Non-HDL Cholesterol

Introduction to Non-HDL Cholesterol

The American College of Cardiology recommends non-HDL cholesterol as a superior predictor of cardiovascular disease compared to LDL cholesterol alone, particularly when triglycerides are elevated 1, 2
Non-HDL cholesterol represents a comprehensive measure of all cholesterol carried in atherogenic, apolipoprotein B-containing particles, including LDL, VLDL, IDL, remnant lipoproteins, and lipoprotein(a), making it a more complete assessment of atherogenic burden than LDL cholesterol alone 1, 3

Non-HDL cholesterol demonstrates stronger associations with cardiovascular outcomes than LDL cholesterol across multiple populations, with a study showing that non-HDL cholesterol levels were strongly predictive of CVD mortality after 19 years of follow-up 2, 7
The predictive value of non-HDL cholesterol has been demonstrated in both men and women, across all age and ethnic groups, and with or without pre-existing CVD 2, 4
Non-HDL cholesterol correlates with coronary calcification, CVD progression, fatty streaks, and raised lesions in coronary arteries 2, 3

The National Cholesterol Education Program (NCEP) recommends non-HDL cholesterol as a secondary treatment target when triglycerides are ≥200 mg/dL, with the target set 30 mg/dL higher than the corresponding LDL cholesterol goal 1, 2, 4
For patients with 0-1 risk factors, the non-HDL cholesterol goal is 190 mg/dL (LDL goal + 30 mg/dL) 1
For patients with 2+ risk factors, the non-HDL cholesterol goal is 160 mg/dL (LDL goal + 30 mg/dL) 1
For patients with CVD or CVD risk equivalents, the non-HDL cholesterol goal is 130 mg/dL (LDL goal + 30 mg/dL) 1, 2

Apolipoprotein B provides a direct measure of the number of atherogenic particles, since each potentially atherogenic lipoprotein particle contains exactly one apo B molecule, and has been shown to be superior to LDL cholesterol in predicting CVD events 2, 3, 6
Apo B has analytical and biological stability and is valid in non-fasting samples, making it a useful alternative to non-HDL cholesterol 6, 8

Non-HDL cholesterol is a significant predictor of atherosclerosis in children and adolescents, and levels in childhood strongly predict adult levels, making it valuable for early risk assessment 11, 2, 4
In patients with diabetes, non-HDL cholesterol predicted 10-year CVD mortality among those with impaired fasting glucose, though not in those with normal fasting glucose 2, 3
When triglycerides are ≥200 mg/dL, non-HDL cholesterol assessment becomes particularly important as it captures remnant lipoproteins that contribute significantly to cardiovascular risk 1, 5

Non-HDL cholesterol should be reported on all routine lipid profiles and used regularly in dyslipidemia management for optimal cardiovascular disease prevention, with a meta-analysis supporting a 1:1 relationship between percent non-HDL cholesterol lowering and percent cardiovascular risk reduction 1, 2
Treatment response should be monitored using non-HDL cholesterol when triglycerides are elevated, as it provides more accurate assessment than LDL cholesterol alone 2, 7